Abstract
The antiphospholipid syndrome (APS) identifies a condition at increased risk of vascular occlusion and/or pregnancy complications. Patients are defined as having APS if they have at least one clinical (vascular occlusion and/or pregnancy complications) and one laboratory criterion at the same time. The laboratory criteria that define APS are repeated positivity (confirmed 12weeks apart) for lupus anticoagulants and/or antibodies targeted against cardiolipin or β 2-glycoprotein I immobilized on solid surfaces. Over the years, APS has attracted the interest of many medical specialties. The aim of this review is to provide an update on (i) the laboratory criteria that determine the presence of APS, (ii) how the antibodies increase the risk of vascular occlusion and foetal loss and (iii) the treatment of the related clinical events.
| Original language | English |
|---|---|
| Pages (from-to) | 110-122 |
| Number of pages | 13 |
| Journal | Journal of Internal Medicine |
| Volume | 270 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Aug 2011 |
Fingerprint
Keywords
- Arterial thromboembolism
- Foetal loss
- Laboratory testing
- Pregnancy complications
- Venous thromboembolism
ASJC Scopus subject areas
- Internal Medicine
Cite this
Antiphospholipid syndrome : Laboratory detection, mechanisms of action and treatment. / Tripodi, A.; de Groot, P. G.; Pengo, V.
In: Journal of Internal Medicine, Vol. 270, No. 2, 08.2011, p. 110-122.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antiphospholipid syndrome
T2 - Laboratory detection, mechanisms of action and treatment
AU - Tripodi, A.
AU - de Groot, P. G.
AU - Pengo, V.
PY - 2011/8
Y1 - 2011/8
N2 - The antiphospholipid syndrome (APS) identifies a condition at increased risk of vascular occlusion and/or pregnancy complications. Patients are defined as having APS if they have at least one clinical (vascular occlusion and/or pregnancy complications) and one laboratory criterion at the same time. The laboratory criteria that define APS are repeated positivity (confirmed 12weeks apart) for lupus anticoagulants and/or antibodies targeted against cardiolipin or β 2-glycoprotein I immobilized on solid surfaces. Over the years, APS has attracted the interest of many medical specialties. The aim of this review is to provide an update on (i) the laboratory criteria that determine the presence of APS, (ii) how the antibodies increase the risk of vascular occlusion and foetal loss and (iii) the treatment of the related clinical events.
AB - The antiphospholipid syndrome (APS) identifies a condition at increased risk of vascular occlusion and/or pregnancy complications. Patients are defined as having APS if they have at least one clinical (vascular occlusion and/or pregnancy complications) and one laboratory criterion at the same time. The laboratory criteria that define APS are repeated positivity (confirmed 12weeks apart) for lupus anticoagulants and/or antibodies targeted against cardiolipin or β 2-glycoprotein I immobilized on solid surfaces. Over the years, APS has attracted the interest of many medical specialties. The aim of this review is to provide an update on (i) the laboratory criteria that determine the presence of APS, (ii) how the antibodies increase the risk of vascular occlusion and foetal loss and (iii) the treatment of the related clinical events.
KW - Arterial thromboembolism
KW - Foetal loss
KW - Laboratory testing
KW - Pregnancy complications
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=79959382588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959382588&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2796.2011.02362.x
DO - 10.1111/j.1365-2796.2011.02362.x
M3 - Article
C2 - 21323768
AN - SCOPUS:79959382588
VL - 270
SP - 110
EP - 122
JO - Journal of Internal Medicine
JF - Journal of Internal Medicine
SN - 0954-6820
IS - 2
ER -